The Subcutaneous Shield: Why Switching Formats May Protect Less than Pharma Expects
As the biggest biologics approach loss of exclusivity, originators are moving patients to subcutaneous versions protected by newer patents. Keytruda, Opdivo, and Darzalex all follow this playbook. But the earlier precedent, the realities of combination ...read more
published on Oct 27, 2026